Established in 1984, the Institute of Microbial Technology (IMTech) is one among the chain of 37 national laboratories, 6 units and 39 outreach centres of the Council of Scientific & Industrial Research. Set-up to be a fore-runner in the niche domain of microbial biotechnology, the Institute in its initial years functioned from a start-up laboratory that provided a truly world-class R&D ambience in an area of over 10,000 sq. ft. to its researchers.
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ORENCIA® (abatacept) for the prevention of moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors. There are no approved therapies for the prevention of acute GvHD, a potentially life-threatening medical complication that can impact patients receiving such transplants for the treatment of certain genetic diseases and hematologic cancers.

